The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Quinolinic acid upregulates chemokine production and chemokine receptor expression in astrocytes
Abstract
Within the brain, quinolinic acid (QUIN) is an important neurotoxin, especially in AIDS dementia complex (ADC). Its production by monocytic lineage cells is increased in the context of inflammation. However, it is not known whether QUIN promotes inflammation. Astrocytes are important in immunoregulation within the brain and so we chose to examine the effects of QUIN on the astrocyte. Using purified primary human fetal astrocyte cultures, we determined chemokine production using ELISA assays and RT‐PCR and chemokine receptor expression using immunocytochemistry and RT‐PCR with QUIN in comparison to TNFα, IL‐1β, and IFNγ. We found that QUIN induces astrocytes to produce large quantities of MCP‐1 (CCL2) and lesser amounts of RANTES (CCL5) and IL‐8 (CXCL8). QUIN also increases SDF‐1α (CXCL12), HuMIG (CXCL9), and fractalkine (CX 3 CL1) mRNA expression. Moreover, QUIN leads to upregulation of the chemokine receptor expression of CXCR4, CCR5, and CCR3 in human fetal astrocytes. Most of these effects were comparable to those induced by TNFα, IL‐1β, and IFNγ. The present work represents the first evidence that QUIN induces chemokine and chemokine receptor expression in astrocytes and is at least as potent as classical mediators such as inflammatory cytokines. These results suggest that QUIN may be critical in the amplification of brain inflammation, particularly in ADC. GLIA 41:371–381, 2003. © 2003 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Expression of CX 3 CR1 chemokine receptors on neurons and their role in neuronal survival
Meucci, O., Fatatis, A., Simen, A. A., & Miller, R. J. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.090017497 · Cited by 385 · cited 2×
“Furthermore, fractalkine possesses neuroprotective properties against platelet-activating factor (PAF) and viral proteins like Tat and gp120 (Meucci et al., 2000) and antiapoptotic properties on microglial cells (Boehme et al., 2000).”
BackgroundHayashi, M., Luo, Y., Laning, J., Strieter, R. M., & Dorf, M. E. (1995) · Journal of Neuroimmunology · doi:10.1016/0165-5728(95)00064-9 · Cited by 226
Cited by
Tryptophan metabolism in health and disease
Xue, C., Li, G., Zheng, Q., Gu, X., Shi, Q., Su, Y., Chu, Q., Yuan, X., Bao, Z., Lu, J., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.06.004 · Cited by 961
Santomasso, B. D., Park, J. H., Salloum, D., Riviere, I., Flynn, J., Mead, E., Halton, E., Wang, X., Senechal, B., Purdon, T., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1319 · Cited by 942
The kynurenine pathway: a finger in every pie
Savitz, J. (2020) · Molecular Psychiatry · doi:10.1038/s41380-019-0414-4 · Cited by 756
Raison, C. L., Dantzer, R., Kelley, K. W., Lawson, M. A., Woolwine, B. J., Vogt, G., Spivey, J. R., Saito, K., & Miller, A. H. (2010) · Molecular Psychiatry · doi:10.1038/mp.2009.116 · Cited by 630
Quinolinic acid, the inescapable neurotoxin
Guillemin, G. J. (2012) · The FEBS Journal · doi:10.1111/j.1742-4658.2012.08485.x · Cited by 595
Self-citationGuillemin, G. J., & Brew, B. J. (2004) · Journal of Leukocyte Biology · doi:10.1189/jlb.0303114 · Cited by 525
Self-citationBidirectional Microglia–Neuron Communication in Health and Disease
Szepesi, Z., Manouchehrian, O., Bachiller, S., & Deierborg, T. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00323 · Cited by 459
“, 2016) as perivascular astrocytes have been identified as the most common and predominant source of CCL2 in the CNS in various neuroinflammatory conditions (Andjelkovic et al., 2002; Guillemin et al., 2003).”
BackgroundInflammation Effects on Motivation and Motor Activity: Role of Dopamine
Felger, J. C., & Treadway, M. T. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.143 · Cited by 442
Imaging the Role of Inflammation in Mood and Anxiety-related Disorders
Felger, J. C. (2018) · Current Neuropharmacology · doi:10.2174/1570159x15666171123201142 · Cited by 427
Hill, W. D., Hess, D. C., Martin-Studdard, A., Carothers, J. J., Zheng, J., Hale, D., Maeda, M., Fagan, S. C., Carroll, J. E., & Conway, S. J. (2004) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/63.1.84 · Cited by 403
Lovelace, M. D., Varney, B., Sundaram, G., Lennon, M. J., Lim, C. K., Jacobs, K., Guillemin, G. J., & Brew, B. J. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.03.024 · Cited by 393
Self-citationQuinolinic acid: an endogenous neurotoxin with multiple targets
Lugo-Huitrón, R., Ugalde Muñiz, P., Pineda, B., Pedraza-Chaverrí, J., Ríos, C., & Pérez-de la Cruz, V. (2013) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2013/104024 · Cited by 394
LI, M., & RANSOHOFF, R. (2008) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2007.11.003 · Cited by 352
An expanding range of targets for kynurenine metabolites of tryptophan
Stone, T. W., Stoy, N., & Darlington, L. G. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.09.006 · Cited by 344
Indoleamine 2,3 dioxygenase and quinolinic acid Immunoreactivity in Alzheimer's disease hippocampus
Guillemin, G. J., Brew, B. J., Noonan, C. E., Takikawa, O., & Cullen, K. M. (2005) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2005.00655.x · Cited by 330
Self-citationMüller, M., Carter, S., Hofer, M. J., & Campbell, I. L. (2010) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2010.01089.x · Cited by 293
Kynurenine and its metabolites in Alzheimer's disease patients
Gulaj, E., Pawlak, K., Bien, B., & Pawlak, D. (2010) · Advances in Medical Sciences · doi:10.2478/v10039-010-0023-6 · Cited by 285
The kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disorders
Stone, T. W., & Darlington, L. G. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12230 · Cited by 271
The kynurenine pathway of tryptophan degradation as a drug target
Schwarcz, R. (2004) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2003.10.006 · Cited by 265
Stuart, M. J., & Baune, B. T. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.02.001 · Cited by 259
Mithaiwala, M. N., Santana-Coelho, D., Porter, G. A., & O’Connor, J. C. (2021) · Cells · doi:10.3390/cells10061548 · Cited by 190
IDO and Kynurenine Metabolites in Peripheral and CNS Disorders
Huang, Y.-S., Ogbechi, J., Clanchy, F. I., Williams, R. O., & Stone, T. W. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00388 · Cited by 187
Ting, K. K., Brew, B. J., & Guillemin, G. J. (2009) · Journal of Neuroinflammation · doi:10.1186/1742-2094-6-36 · Cited by 166
Self-citationNeuropathology of mood disorders: Do we see the stigmata of inflammation?
Mechawar, N., & Savitz, J. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.212 · Cited by 165
Involvement of the kynurenine pathway in the pathogenesis of Parkinson's disease
Lim, C. K., Fernández-Gomez, F. J., Braidy, N., Estrada, C., Costa, C., Costa, S., Bessede, A., Fernandez-Villalba, E., Zinger, A., Herrero, M. T., et al. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.12.009 · Cited by 159
“Within the brain, QUIN is only produced by activated microglia and infiltrating macrophages (Guillemin et al., 2003b), but not by neurons or astrocytes (Guillemin et al., 2005c) (Fig.”
BackgroundSelf-citationThe kynurenine pathway and inflammation in amyotrophic lateral sclerosis
Chen, Y., Stankovic, R., Cullen, K. M., Meininger, V., Garner, B., Coggan, S., Grant, R., Brew, B. J., & Guillemin, G. J. (2010) · Neurotoxicity Research · doi:10.1007/s12640-009-9129-7 · Cited by 141
“IFN-c is the most potent inducer of IDO and can activate and upregulate the KP. In the brain, stimulation of microglia and perivascular macrophages by IFN-c increases QUIN production (Heyes et al. 1996), which, in turn, up-regulates chemokine production and chemokine receptor expression in astrocytes, further propagat…”
BackgroundSelf-citationEffects of inflammation on the kynurenine pathway in schizophrenia—a systematic review
Pedraz-Petrozzi, B., Elyamany, O., Rummel, C., & Mulert, C. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-1721-z · Cited by 119
The role of dopamine in inflammation-associated depression: mechanisms and therapeutic implications
Felger, J. C. (2016) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2016_13 · Cited by 115
Implications for the kynurenine pathway and quinolinic acid in amyotrophic lateral sclerosis
Guillemin, G. J., Meininger, V., & Brew, B. J. (2005) · Neurodegenerative Diseases · doi:10.1159/000089622 · Cited by 105
Self-citationMonocyte Chemoattractant Protein-1 Levels Are Associated with Major Depressive Disorder
Proma, M. A., Daria, S., Nahar, Z., Ashraful Islam, S. M., Bhuiyan, M. A., & Islam, M. R. (2022) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2021-0132 · Cited by 29
Metadata
- Authors
- Guillemin, G. J., Croitoru‐Lamoury, J., Dormont, D., Armati, P. J., & Brew, B. J.
- Venue
- Glia
- Publisher
- Wiley
- Published
- 2003-01-23
- Volume
- 41
- Issue
- 4
- Pages
- 371-381
- ISSN
- 0894-1491 (ISSN-L)
- 1098-1136
- OpenAlex
- W2076249077
- Cited by
- 173
- References
- 2
- FWCI
- 4.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.